<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876511</url>
  </required_header>
  <id_info>
    <org_study_id>J1365</org_study_id>
    <secondary_id>MK-3475-016</secondary_id>
    <secondary_id>NA_00085756</secondary_id>
    <nct_id>NCT01876511</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors</brief_title>
  <official_title>Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T
      cells) is effective (anti-tumor activity) and safe in three different patient populations.
      These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative
      colon cancer 3. patients with other MSI positive cancers, and 4. patients with MSI negative
      cancer with a mutator phenotype.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune-related progression free survival (irPFS) rate at 20 weeks in patients with MSI positive and negative colorectal adenocarcinoma using immune related response criteria (irRC)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (irORR) at 20 weeks in patients with MSI positive and negative colorectal adenocarcinoma using immune related response criteria (irRC)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune-related progression free survival (irPFS) rate in patients with MSI positive non-colorectal adenocarcinoma using immune related response criteria (irRC) at 20 weeks</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>objective response rate in patients with MSI-negative cancer with a mutator phenotype using RECIST 1.1 criteria</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>irPFS and PFS in patients with MSI positive and negative tumors at 28 weeks using irRC and RECIST 1.1</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate and disease control rate in patients with MSI positive and negative tumors</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing immune-related toxicities (IRAEs)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does MSI as a marker predict treatment response</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify alternative markers of MSI status. This includes but is not limited to MLH 1, MSH 2, MSH 6, PMS2, BRAF pV600E, and TGFBR2.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">171</enrollment>
  <condition>MSI Positive Colorectal Cancer</condition>
  <condition>MSI Negative Colorectal Cancer</condition>
  <condition>MSI Positive Non-Colorectal Cancers</condition>
  <condition>High Tumor Mutation Burden</condition>
  <arm_group>
    <arm_group_label>MSI Positive Colorectal Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MSI Negative Colorectal Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MSI Positive Non-Colorectal Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MSI Negative with Mutator Phenotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3475</intervention_name>
    <description>MK-3475 10 mg/kg every 14 days</description>
    <arm_group_label>MSI Positive Colorectal Cancer</arm_group_label>
    <arm_group_label>MSI Negative Colorectal Cancer</arm_group_label>
    <arm_group_label>MSI Positive Non-Colorectal Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3475</intervention_name>
    <description>MK-3475 200mg flat dose every 21 days</description>
    <arm_group_label>MSI Negative with Mutator Phenotype</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Arm 1 only: Patients with MSI positive colorectal cancer 2. Arm 2 only: Patients with
        MSI negative colorectal cancer 3. Arm 3 only: Patients with MSI positive non-colorectal
        cancer 4. Arm 4 only: patients with hypermutated MSI negative cancer 4. Have measurable
        disease 5. ECOG Performance Status of 0 to 1 6. Adequate organ function as defined by
        study-specified laboratory tests 7. Must use acceptable form of birth control through the
        study and for 28 days after final dose of study drug 8. Signed informed consent form 9.
        Willing and able to comply with study procedures 10. Agree to have a biopsy of their cancer
        11. Patients with colon cancer must have received at least two prior cancer therapy
        regimens.

        12. Patients with other cancer types must have received at least one prior cancer therapy
        13. Progressive disease

        Exclusion Criteria:

          1. Patients with uncontrolled intercurrent illness, including but not limited to ongoing
             or active infection, systematic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia or psychiatric condition that would limit compliance with study
             requirements. .

          2. Patients who have had chemotherapy or biological cancer therapy within 2 weeks prior
             to the first dose of study drug

          3. Patients who have had radiation within 2 weeks prior to the first dose of study drug

          4. Patients who have undergone major surgery within 4 weeks of dosing of investigational
             agent

          5. Patients who have received another investigational product or investigational device
             within 4 weeks prior to receiving study drug

          6. Patients who have received any of the following concomitant therapy: IL-2, interferon,
             or other non-study immunotherapy regimens, immunosuppressive agents, other
             investigational therapies or chronic use of systemic corticosteroids within one week
             prior to first dose of study drug

          7. Patients who have received a live vaccine within 4 weeks prior to or after any dose of
             MK-3475 (exception: inactivated flu vaccines)

          8. Patients who have received growth factors, including but not limited to
             granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony
             stimulating factor (GM-CSF), erythropoietin, etc. within 2 weeks of study drug
             administration

          9. Patient who have had prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4 antibodies

         10. Patients with history of any autoimmune disease:inflammatory bowel disease, (including
             ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive
             sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis, CNS
             or motor neuropathy considered to be of autoimmune origin.

         11. Patients who have known history of infection with HIV, hepatitis B, or hepatitis C

         12. Patients with evidence of interstitial lung disease

         13. Systemically active steroid use

         14. Patients on home oxygen

         15. Patients with oxygen saturation of &lt;92% on room air by pulse oximetry

         16. Pregnant or lactating

         17. Conditions, including alcohol or drug dependence, or intercurrent illness that would
             affect the patient's ability to comply with study visits and procedures

         18. Patient with known active central nervous system metastases and/or carcinomatous
             meningitis.

         19. Patients with primary brain tumors.

         20. Requires any other form of systemic or localized antineoplastic therapy while on study

         21. Has any tissue or organ allograft

         22. Patients with history of allogeneic hematopoeitic stem cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Fisher, MD</last_name>
      <email>georgeaf@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>George Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>sartosu@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Dung Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigator Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, NIH</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hays, MD</last_name>
      <phone>614-293-6529</phone>
      <email>John.Hays@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>John Hays, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Crocenzi, MD</last_name>
      <email>Todd.Crocenzi@providence.org</email>
    </contact>
    <investigator>
      <last_name>Todd Crocenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim R Binder, MD</last_name>
      <phone>215-360-0735</phone>
      <email>Kim.ReissBinder@uphsupenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kim R Binder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Lee, MD, PhD</last_name>
      <email>leejj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>James Lee, MD; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.</citation>
    <PMID>28596308</PMID>
  </reference>
  <reference>
    <citation>Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.</citation>
    <PMID>26028255</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MSI</keyword>
  <keyword>MSS</keyword>
  <keyword>MLH 1</keyword>
  <keyword>MSH 2</keyword>
  <keyword>MSH 6</keyword>
  <keyword>PMS2</keyword>
  <keyword>BRAF pV600E</keyword>
  <keyword>TGFBR2</keyword>
  <keyword>Mutation load</keyword>
  <keyword>tumor mutation load</keyword>
  <keyword>mutation burden</keyword>
  <keyword>tumor mutation burden</keyword>
  <keyword>hypermutation</keyword>
  <keyword>POLE</keyword>
  <keyword>MSI Negative with Mutator Phenotype (High Tumor Mutation Burden)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

